Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma

Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma

BACKROUND: Not all patients with hepatocellular carcinoma (HCC) benefit from treatment with molecular targeted agents such as sorafenib. We investigated whether New-FP (fine-powder cisplatin and 5-fluorouracil), a hepatic arterial infusion chemotherapy regimen, is more favorable than sorafenib as an...

Full description

Bibliographic Details
Main Authors: Hideki Iwamoto, Takashi Niizeki, Hiroaki Nagamatsu, Kazuomi Ueshima, Takako Nomura, Teiji Kuzuya, Kazuhiro Kasai, Yohei Kooka, Atsushi Hiraoka, Rie Sugimoto, Takehiro Yonezawa, Akio Ishihara, Akihiro Deguchi, Hirotaka Arai, Shigeo Shimose, Tomotake Shirono, Masahito Nakano, Shusuke Okamura, Yu Noda, Naoki Kamachi, Miwa Sakai, Hiroyuki Suzuki, Hajime Aino, Norito Matsukuma, Satoru Matsugaki, Kei Ogata, Yoichi Yano, Takato Ueno, Masahiko Kajiwara, Satoshi Itano, Kunitaka Fukuizumi, Hiroshi Kawano, Kazunori Noguchi, Masatoshi Tanaka, Taizo Yamaguchi, Ryoko Kuromatsu, Atsushi Kawaguchi, Hironori Koga, Takuji Torimura, New FP Study Group, Kurume Liver Cancer Study Group of Japan
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
hepatocellular carcinoma
intra-arterial infusions
sorafenib
molecular targeted therapy
Online Access:https://www.mdpi.com/2072-6694/13/4/646

Internet

https://www.mdpi.com/2072-6694/13/4/646

Similar Items